People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alseres Pharmaceuticals Inc /De | — | Biotechnology | Seed | $5.9M | $44.4M | 2009 |
Henry Brem at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Henry Brem on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Robert E. Langer | 1 | 3 |
| John T. Preston | 1 | 3 |
| Gary E. Frashier | 1 | 2 |
| Peter G. Savas | 1 | 2 |
| Michael J. Mullen | 1 | 2 |
| Mark Pykett | 1 | 2 |
| Henry L.S. Brem | 1 | 1 |
| Mark G. Pykett | 1 | 1 |
| Kenneth L. Rice, Jr. | 1 | 1 |
| William L.S. Guinness | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.